Cargando…

Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse

Although first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy is effective for treating EGFR-mutant non–small cell lung cancer (NSCLC), it is now understood that drug-tolerant persister (DTP) cells escaping from initial treatment eventually drives drug resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nie, Meng, Chen, Na, Pang, Huanhuan, Jiang, Tao, Jiang, Wei, Tian, Panwen, Yao, LiAng, Chen, Yangzi, DeBerardinis, Ralph J., Li, Weimin, Yu, Qitao, Zhou, Caicun, Hu, Zeping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9566900/ https://www.ncbi.nlm.nih.gov/pubmed/36048538 http://dx.doi.org/10.1172/JCI160152

Ejemplares similares

PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs
por: Bai, Yuchen, et al.
Publicado: (2018)

Identifying metabolomic features that predict metastasis of melanoma from a primary site
por: Shi, Xiaolei, et al.
Publicado: (2014)

α-ketobutyrate links alterations in cystine metabolism to glucose oxidation in mtDNA mutant cells
por: Lesner, Nicholas P., et al.
Publicado: (2020)

Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases
por: Zhang, Guowei, et al.
Publicado: (2017)

Metabolic heterogeneity in cancer
por: DeBerardinis, Ralph J
Publicado: (2014)

Q&A: Targeting metabolism to diagnose and treat cancer
por: DeBerardinis, Ralph J
Publicado: (2014)

The abundance of metabolites related to protein methylation correlates with the metastatic capacity of human melanoma xenografts
por: Shi, Xiaolei, et al.
Publicado: (2017)

Pyruvate dehydrogenase activity is required for optimal growth under lipid deficient conditions
por: Rajagopalan, Kartik, et al.
Publicado: (2014)

First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease
por: Xu, Qinghua, et al.
Publicado: (2019)

Fundamentals of cancer metabolism
por: DeBerardinis, Ralph J., et al.
Publicado: (2016)

From “N of 1” to N of more
por: DeBerardinis, Ralph J., et al.
Publicado: (2015)

Clinicopathological Characteristics And EGFR-TKIs Efficacies In Lung Squamous Cell Carcinoma Patients Harboring An EGFR Sensitizing Mutation
por: Zhou, Shaozhang, et al.
Publicado: (2019)

Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer—an option for overcoming EGFR-TKI resistance
por: Han, Ruoshuang, et al.
Publicado: (2021)

FASN deficiency induces a cytosol-to-mitochondria citrate flux to mitigate detachment-induced oxidative stress
por: Dai, Wenting, et al.
Publicado: (2023)

Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report
por: Chen, Shubin, et al.
Publicado: (2023)

Vitamin B6-dependent epilepsy due to pyridoxal phosphate-binding protein (PLPBP) defect – First case report from Pakistan and review of literature
por: Ahmed, Sibtain, et al.
Publicado: (2020)

Diagnostic accuracy of droplet digital PCR for detection of EGFR T790M mutation in circulating tumor DNA
por: Zhang, Rui, et al.
Publicado: (2018)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

A nanobuffer reporter library for fine-scale imaging and perturbation of endocytic organelles
por: Wang, Chensu, et al.
Publicado: (2015)

Human tenocytes are stimulated to proliferate by acetylcholine through an EGFR signalling pathway
por: Fong, Gloria, et al.
Publicado: (2012)

Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
por: Zhang, Shi-Ling, et al.
Publicado: (2023)

Metabolomics in drug research and development: The recent advances in technologies and applications
por: Pang, Huanhuan, et al.
Publicado: (2023)

Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial
por: Jiang, Tao, et al.
Publicado: (2021)

Exosomes transmit T790M mutation‐induced resistance in EGFR‐mutant NSCLC by activating PI3K/AKT signalling pathway
por: Liu, Xiaozhen, et al.
Publicado: (2020)

A Pan-Cancer Assessment of RB1/TP53 Co-Mutations
por: Cai, Ling, et al.
Publicado: (2022)

Dissecting molecular, pathological, and clinical features associated with tumor neural/neuroendocrine heterogeneity
por: Cai, Ling, et al.
Publicado: (2023)

A Comparative Study of Neuroendocrine Heterogeneity in Small Cell Lung Cancer and Neuroblastoma
por: Cai, Ling, et al.
Publicado: (2023)

Oxidative stress inhibits distant metastasis by human melanoma cells
por: Piskounova, Elena, et al.
Publicado: (2015)

Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas
por: Gong, Yixuan, et al.
Publicado: (2007)

Adenocarcinoma of High-Grade Patterns Associated with Distinct Outcome of First-Line Chemotherapy or EGFR-TKIs in Patients of Relapsed Lung Cancer
por: Yu, Xiaofei, et al.
Publicado: (2021)

Assessing consistency across functional screening datasets in cancer cells
por: Cai, Ling, et al.
Publicado: (2021)

Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer
por: Cheng, Ningning, et al.
Publicado: (2015)

Metabolic plasticity maintains proliferation in pyruvate dehydrogenase deficient cells
por: Rajagopalan, Kartik N., et al.
Publicado: (2015)

Nebulin binding impedes mutant desmin filament assembly
por: Baker, Laura K., et al.
Publicado: (2013)

Genomic regression analysis of coordinated expression
por: Cai, Ling, et al.
Publicado: (2017)

CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells
por: Kim, Jiyeon, et al.
Publicado: (2017)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
por: Tang, Kejing, et al.
Publicado: (2018)

The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer
por: Zhao, Chao, et al.
Publicado: (2020)

Outcomes of salvage lung resections in advanced EGFR ‐mutant lung adenocarcinomas under EGFR TKIs
por: Chen, Ying‐Yuan, et al.
Publicado: (2021)

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells
por: Wu, Hong, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_eoip0jkdvv0arcdlgt6h1pmab7